Gilead Sciences Inc. (GILD): Price and Financial Metrics

GILD POWR Grades

• GILD scores best on the Value dimension, with a Value rank ahead of 97.46% of US stocks.
• The strongest trend for GILD is in Sentiment, which has been heading down over the past 179 days.
• GILD ranks lowest in Momentum; there it ranks in the 26th percentile.

GILD Stock Summary

• GILEAD SCIENCES INC's market capitalization of $98,603,230,065 is ahead of 97.88% of US-listed equities.
• With a one year PEG ratio of 88.54, GILEAD SCIENCES INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 76.01% of US stocks.
• GILD's went public 31.36 years ago, making it older than 84.55% of listed US stocks we're tracking.
• If you're looking for stocks that are quantitatively similar to GILEAD SCIENCES INC, a group of peers worth examining would be ADI, GSK, AMGN, BA, and ATVI.
• GILD's SEC filings can be seen here. And to visit GILEAD SCIENCES INC's official web site, go to www.gilead.com.

GILD Valuation Summary

• GILD's price/earnings ratio is 17.6; this is 26.97% lower than that of the median Healthcare stock.
• Over the past 243 months, GILD's EV/EBIT ratio has gone up 45.4.

Below are key valuation metrics over time for GILD.

GILD Growth Metrics

Its 4 year net income to common stockholders growth rate is now at -60.73%.
• Its 5 year net cashflow from operations growth rate is now at -41.74%.
• The 5 year net income to common stockholders growth rate now stands at -60.73%.

Over the past 34 months, GILD's revenue has gone up $4,565,000,000.

The table below shows GILD's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2022-12-31	27,281	9,072	4,592
2022-09-30	27,136	9,710	3,334
2022-06-30	27,515	10,100	4,137
2022-03-31	27,472	10,614	4,515
2021-12-31	27,305	11,384	6,225
2021-09-30	27,482	10,095	7,394

GILD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• GILD has a Quality Grade of B, ranking ahead of 89.87% of graded US stocks.
• GILD's asset turnover comes in at 0.406 -- ranking 114th of 682 Pharmaceutical Products stocks.
• ENTA, RDUS, and ADMS are the stocks whose asset turnover ratios are most correlated with GILD.

The table below shows GILD's key quality metrics over time.